How'd you fix McKesson's revenue issues in 2026?
Direct Answer: McKesson's real issue isn't revenue growth—US Pharma is up 18% YoY to $327.7B (fiscal 2025, 10-K). The problem is margin dilution from GLP-1 scale and Medical-Surgical Solutions near-flatline (1% growth to $11.4B). A CRO woul…
Read full answer ↗